AR070367A1 - Formulaciones de flibanserina - Google Patents
Formulaciones de flibanserinaInfo
- Publication number
- AR070367A1 AR070367A1 ARP090100504A ARP090100504A AR070367A1 AR 070367 A1 AR070367 A1 AR 070367A1 AR P090100504 A ARP090100504 A AR P090100504A AR P090100504 A ARP090100504 A AR P090100504A AR 070367 A1 AR070367 A1 AR 070367A1
- Authority
- AR
- Argentina
- Prior art keywords
- sexual
- disorders
- disorder
- flibanserin
- pharmaceutical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 abstract 5
- 229960002053 flibanserin Drugs 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000001568 sexual effect Effects 0.000 abstract 4
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003002 pH adjusting agent Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 239000003340 retarding agent Substances 0.000 abstract 2
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 2
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000004483 Dyspareunia Diseases 0.000 abstract 1
- 206010013954 Dysphoria Diseases 0.000 abstract 1
- 206010024419 Libido decreased Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000029899 Sexual aversion disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000022371 chronic pain syndrome Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 208000018578 heart valve disease Diseases 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 229920003130 hypromellose 2208 Polymers 0.000 abstract 1
- 229940031707 hypromellose 2208 Drugs 0.000 abstract 1
- 229920003125 hypromellose 2910 Polymers 0.000 abstract 1
- 229940031672 hypromellose 2910 Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 229960002900 methylcellulose Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 206010046947 vaginismus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Sistemas farmacéuticos de liberacion que comprenden una cantidad terapéuticamente eficaz de flibanserina. Reivindicacion 1: Composicion farmacéutica caracterizada porque comprende flibanserina en su forma amorfa y al menos un excipiente adicional. Reivindicacion 3: Composicion farmacéutica de acuerdo con la reivindicacion 2 caracterizada porque el patron de difraccion de polvo de rayos X de la flibanserina en la formulacion farmacéutica muestra un ôheloö amorfo superpuesto por picos de difraccion de flibanserina cristalina. Reivindicacion 5: Sistema farmacéutico de liberacion caracterizado porque comprende o consiste esencialmente en I) un nucleo que comprende a) flibanserina o un derivado farmacéuticamente aceptable de la misma como ingrediente activo en forma cristalina y/o amorfa; b) uno o más excipientes de supersaturacion seleccionados entre el grupo consistente en metilcelulosas, hipromelosa 2208, hipromelosa 2910 o hipromelosa 2906; c) uno o más modificadores del pH farmacéuticamente aceptables, donde los modificadores del pH están presentes en una cantidad de 45-90% en peso del nucleo; d) opcionalmente uno o más aditivos; y en el caso de un sistema de liberacion extendida e) opcionalmente uno o más agentes retardantes; y/o II) una o más capas retardantes que comprenden uno o más agentes retardantes que rodean al ingrediente activo, pero no necesariamente en contacto directo con el mismo. Reivindicacion 16: Uso de un sistema de liberacion farmacéutica segun una o más de las reivindicaciones 1 a 15 caracterizado porque es para la fabricacion de un medicamento para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, ansiedad, trastornos del sueno y sexuales ( trastorno del deseo sexual hipoactivo, trastornos premenstruales como disforia premenstrual, síndrome premenstrual, trastorno disforico premenstrual; trastorno de aversion sexual, trastorno de despertar sexual , trastorno orgásmico, trastornos de dolor sexual como dispareunia, vaginismo, trastorno de dolor sexual sin coito, disfuncion sexual debida a una afeccion médica general y disfuncion sexual inducida por sustancias) psicosis, esquizofrenia, trastornos de personalidad, trastornos orgánicos mentales, trastornos mentales en la infancia, agresividad, deterioro de la memoria asociado con el envejecimiento, neuroproteccion, enfermedades neurodegenerativa, isquemia cerebral de diversos orígenes, anorexia nerviosa, trastorno de hiperactividad con déficit de la atencion (ADHD), obesidad, incontinencia urinaria, dolor cronico y cardiopatía valvular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08101599A EP2090297A1 (en) | 2008-02-13 | 2008-02-13 | Formulations of flibanserin |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070367A1 true AR070367A1 (es) | 2010-03-31 |
Family
ID=39431170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100504A AR070367A1 (es) | 2008-02-13 | 2009-02-12 | Formulaciones de flibanserina |
Country Status (13)
Country | Link |
---|---|
US (3) | US20110045090A1 (es) |
EP (2) | EP2090297A1 (es) |
JP (1) | JP2011511818A (es) |
CN (1) | CN101951894A (es) |
AR (1) | AR070367A1 (es) |
BR (1) | BRPI0908455A2 (es) |
CA (1) | CA2714542A1 (es) |
CL (1) | CL2009000322A1 (es) |
IL (1) | IL206577A0 (es) |
MX (1) | MX2010008852A (es) |
PE (1) | PE20091418A1 (es) |
TW (1) | TW200940057A (es) |
WO (1) | WO2009100886A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014517843A (ja) * | 2011-05-24 | 2014-07-24 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬組成物用の圧縮コア |
CN106456640B (zh) | 2014-05-29 | 2021-05-14 | 诺华股份有限公司 | 色瑞替尼制剂 |
CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
EP3331502B1 (en) * | 2015-08-07 | 2021-05-26 | Santa Farma Ilaç Sanayi A.S. | Controlled release propiverine formulations |
WO2017055935A1 (en) * | 2015-09-30 | 2017-04-06 | Symed Labs Limited | Amorphous co-precipitates of flibanserin |
CN106866546A (zh) * | 2015-12-10 | 2017-06-20 | 常州爱诺新睿医药技术有限公司 | 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
CN110251475B (zh) * | 2019-07-25 | 2021-07-16 | 沈阳信康药物研究有限公司 | 一种帕利哌酮片剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
DE19961334A1 (de) * | 1999-12-17 | 2001-06-21 | Roehm Gmbh | Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere |
KR100899297B1 (ko) | 2001-08-02 | 2009-05-26 | 비다켐 에스. 피. 에이. | 플리반세린의 안정한 다형체, 이의 기술적 제조 방법 및 이를 포함하는 약제학적 조성물 |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
UA80135C2 (en) * | 2002-05-22 | 2007-08-27 | Boehringer Ingelheim Pharma | Pharmaceutical composition containing flibanserin polymorph a |
KR20070043806A (ko) * | 2004-07-29 | 2007-04-25 | 사노피-아벤티스 | pH에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제 |
EP1896002A4 (en) * | 2005-06-27 | 2009-11-25 | Biovail Lab Int Srl | BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE |
FR2887455B1 (fr) * | 2005-06-28 | 2007-08-10 | Sanofi Aventis Sa | Formulation a liberation prolongee de principes actifs de medicaments |
JP2009510099A (ja) * | 2005-09-30 | 2009-03-12 | スミスクライン・ビーチャム・コーポレイション | 医薬組成物 |
CA2640460C (en) * | 2006-01-27 | 2015-05-26 | Eurand, Inc | Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids |
AU2007286288A1 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
-
2008
- 2008-02-13 EP EP08101599A patent/EP2090297A1/en not_active Withdrawn
-
2009
- 2009-02-11 PE PE2009000195A patent/PE20091418A1/es not_active Application Discontinuation
- 2009-02-11 BR BRPI0908455A patent/BRPI0908455A2/pt not_active IP Right Cessation
- 2009-02-11 CA CA2714542A patent/CA2714542A1/en not_active Abandoned
- 2009-02-11 CN CN2009801052034A patent/CN101951894A/zh active Pending
- 2009-02-11 MX MX2010008852A patent/MX2010008852A/es not_active Application Discontinuation
- 2009-02-11 JP JP2010546257A patent/JP2011511818A/ja active Pending
- 2009-02-11 WO PCT/EP2009/000941 patent/WO2009100886A2/en active Application Filing
- 2009-02-11 US US12/867,097 patent/US20110045090A1/en not_active Abandoned
- 2009-02-11 EP EP09709701A patent/EP2252270A2/en not_active Withdrawn
- 2009-02-12 AR ARP090100504A patent/AR070367A1/es unknown
- 2009-02-12 TW TW098104529A patent/TW200940057A/zh unknown
- 2009-02-12 CL CL2009000322A patent/CL2009000322A1/es unknown
-
2010
- 2010-06-23 IL IL206577A patent/IL206577A0/en unknown
-
2012
- 2012-10-22 US US13/657,147 patent/US20130209519A1/en not_active Abandoned
-
2014
- 2014-12-15 US US14/570,467 patent/US20150224058A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150224058A1 (en) | 2015-08-13 |
CL2009000322A1 (es) | 2010-03-05 |
CA2714542A1 (en) | 2009-08-20 |
CN101951894A (zh) | 2011-01-19 |
WO2009100886A2 (en) | 2009-08-20 |
IL206577A0 (en) | 2010-12-30 |
TW200940057A (en) | 2009-10-01 |
BRPI0908455A2 (pt) | 2015-12-15 |
JP2011511818A (ja) | 2011-04-14 |
EP2090297A1 (en) | 2009-08-19 |
WO2009100886A3 (en) | 2009-11-26 |
MX2010008852A (es) | 2010-09-24 |
EP2252270A2 (en) | 2010-11-24 |
PE20091418A1 (es) | 2009-10-07 |
US20130209519A1 (en) | 2013-08-15 |
US20110045090A1 (en) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070367A1 (es) | Formulaciones de flibanserina | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
JP2014516086A5 (es) | ||
CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
JP2010222367A5 (es) | ||
ECSP11011324A (es) | 3h-imidazo[4,5-c]piridina-6-carboxamidas en calidad de agentes antiinflamatorios | |
CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
CO6251360A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
WO2011093826A3 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
AR087744A1 (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa | |
UY32833A (es) | Antagonistas dp2 y usos del mismo | |
CL2007003289A1 (es) | Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam | |
AU2017364899B2 (en) | Psychotropic agents and uses thereof | |
ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. | |
CL2013002739A1 (es) | Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio. | |
JP2017502059A5 (es) | ||
BRPI0808503B8 (pt) | composto, uso de um composto, e, composição farmacêutica | |
JP2011511818A5 (es) | ||
RU2016136351A (ru) | Пиррол-замещенное производное индолона, способ его получения, включающая его композиция и применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |